Back To Search Results


Editor: Ryan Estevez Updated: 11/10/2023 3:41:45 PM


FDA-Approved Indications

Escitalopram, the (S)-enantiomer of citalopram, is a highly selective serotonin reuptake inhibitor (SSRI). Escitalopram is approved by the U.S. Food and Drug Administration (FDA) for treating major depressive disorder (MDD; unipolar) in adults and adolescents (ages 12 to 17) for both acute and maintenance phases. The FDA recently approved escitalopram for the treatment of generalized anxiety disorder (GAD) in both adults [1] and pediatric patients aged 7 and older.[2] 

Off-Label Uses

Escitalopram is also used off-label for social anxiety disorder, obsessive-compulsive disorder, panic disorder, posttraumatic stress disorder, premenstrual dysphoric disorder, and vasomotor symptoms of menopause.[3][4][5][6]

Mechanism of Action

Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
  • Dropdown arrow Search engine and full access to all medical articles
  • Dropdown arrow 10 free questions in your specialty
  • Dropdown arrow Free CME/CE Activities
  • Dropdown arrow Free daily question in your email
  • Dropdown arrow Save favorite articles to your dashboard
  • Dropdown arrow Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care

Mechanism of Action

SSRIs exert their mechanism of action by binding to the sodium-dependent serotonin transporter protein (SERT) in the presynaptic neuron. SERT is responsible for reuptaking serotonin from the synaptic cleft into the presynaptic neuron. Inactivation of SERT by escitalopram leads to an elevation in synaptic serotonin levels.[7]

Serotonin, also known as 5-hydroxytryptamine (5-HT), is a crucial neurotransmitter that regulates various human behavioral processes, including mood, perception, memory, anger, aggression, fear, stress response, appetite, addiction, and sexuality. The expression of multiple serotonin receptors in brain regions, such as the cortex, limbic system, midbrain, and hindbrain, orchestrates these processes.[8] The brain has 5 primary serotonin receptors—5-HT1A, 5-HT1B, 5-HT4, 5-HT6, and 5-HT7.[9] In total, there are 15 known serotonin receptors, which are also found outside the central nervous system.[8]


Absorption: The pharmacokinetics of escitalopram demonstrate linearity and dose proportionality within the 10 to 30 mg/d dosage range. Notably, food does not affect the absorption of the drug. Peak plasma concentration is typically attained in approximately 5 hours, and steady-state plasma concentrations are achieved within 1 to 2 weeks.[10]

Distribution: Escitalopram has a high volume of distribution (12 L/kg) and a low plasma protein binding (56%). Consequently, it is unlikely to provoke interactions with highly protein-bound drugs.

Metabolism: Escitalopram undergoes hepatic metabolism via CYP3A4 and CYP2C19, yielding S-desmethyl-citalopram (S-DCT) and S-di-desmethyl citalopram (S-DDCT).

Elimination: The terminal half-life of escitalopram varies from 27 to 33 hours. Escitalopram and its metabolites are exerted in the urine.[11]


Available Dosage Forms and Strengths

Escitalopram is administered orally and is available in 2 forms—an oral solution at a concentration of 1 mg/mL and tablets in 5 mg, 10 mg, or 20 mg strengths.

Escitalopram is usually taken once daily, with or without food. The typical initial dose of the medication is 10 mg, with the option to increase after 1 week for symptom management.[10] A 4-week dose reduction is recommended when transitioning escitalopram from another SSRI.

Adult Dosage

The FDA-approved doses are stated in the package insert provided below. However, it is crucial to recognize the need for personalized dosing, as the selection and adjustment of the dosage should be tailored to the severity of depression, response to treatment, and the presence of comorbidities.[12]

  • Major depressive disorder: The starting dosage of escitalopram is 10 mg once daily, and the maximum recommended dosage is 20 mg/d.
  • Generalized anxiety disorder: The initial dosage of escitalopram is 10 mg once daily, and the maximum recommended dosage is 10 mg/d.

Pediatric Dosage

  • Major depressive disorder: The recommended starting dosage of escitalopram for patients aged 12 and older with MDD is 10 mg once daily, and the maximum recommended dosage is 20 mg/d.
  • Generalized anxiety disorder: The recommended starting dosage of escitalopram for patients aged 12 and older with MDD is 10 mg once daily, and the maximum recommended dosage is 20 mg/d.

Specific Patient Populations

Hepatic impairment: Patients with hepatic impairment should take a 10 mg/day dose of escitalopram due to its reduced oral clearance (37%) and doubled half-life.

Renal impairment: Patients with mild-to-moderate renal impairment do not require dosage adjustments. However, it is advisable to exercise caution when using escitalopram in individuals with severe renal impairment with creatinine clearance of less than 20 mL/min.

Pregnancy considerations: Escitalopram is classified as a pregnancy category C medicine. Therefore, close monitoring of patients is advised, and dosage adjustments should be made based on individual patient requirements, as both escitalopram and desmethyl citalopram can traverse the placenta and enter the amniotic fluid.[13]

Breastfeeding considerations: For breastfeeding mothers, it is advisable to administer a relatively lower dose of escitalopram. This precaution is due to the excretion of both escitalopram and its metabolite, desmethyl citalopram (DCT), in breast milk.[14] A single case report of necrotizing enterocolitis has been recorded in a breastfed infant exposed to escitalopram during lactation and pregnancy. However, a causal link to adverse events was not confirmed. A safety assessment deems the use of escitalopram as possibly compatible with breastfeeding.[15] Therefore, if the mother necessitates escitalopram treatment, it is not a reason to discontinue breastfeeding.[16]

Pediatric patients: In a single-dose study involving adolescents aged 12 to 17, the area under the curve (AUC) of escitalopram decreased by 19%, and maximum plasma concentration (Cmax) increased by 26% compared to adult patients. Nevertheless, no dosage adjustment is required for these patients. As mentioned, a patient-centered approach with careful dosage adjustment is essential to optimize pharmacotherapy.

Older patients: In both single- and multiple-dose investigations, the peak plasma concentration of escitalopram remained unchanged, whereas AUC and half-life were increased by approximately 50% in geriatric patients. According to the manufacturer's label, a 10-mg dose of escitalopram is recommended for geriatric patients. Notably, the risk of hyponatremia is elevated in this age group.[17]

Adverse Effects

Although escitalopram and SSRIs have a lower toxicity profile than older antidepressants, they have still been associated with significant adverse effects.[18] The most frequently reported adverse effects include insomnia, sexual dysfunction (particularly reduced libido, anorgasmia, and male ejaculatory delay), nausea, increased sweating, fatigue, and somnolence.[19] QT prolongation and serotonin syndrome are rare but potentially severe adverse effects associated with escitalopram. 

Escitalopram can induce a syndrome of inappropriate antidiuretic hormone secretion (SSRI-induced SIADH), potentially resulting in hyponatremia, particularly in older patients.[20] The symptoms of hyponatremia can vary depending on its severity, ranging from anorexia, nausea, vomiting, fatigue, and headache to more critical conditions such as altered mental status, seizures, and, in extreme cases, coma.[20][21]

QT prolongation is defined as a corrected QT interval on an electrocardiogram (ECG) exceeding 500 ms or an increase of more than 60 ms from the baseline interval.[22] QT prolongation can cause potentially fatal cardiac arrhythmias, including torsades de pointes (TdP).[23] The mechanism underlying QT prolongation involves the inhibition of the inward rectifier current, which extends phase 3 of cardiac repolarization.[22] QTc prolongation is a dose-dependent relationship.[24] According to the American Heart Association (AHA), risk factors for drug-induced Tdp include age 65 or older, female gender, acute coronary syndrome, electrolyte imbalances (such as hypokalemia, hypocalcemia, and hypomagnesemia), and heart failure with reduced ejection fraction (HFrEF). In addition, escitalopram can potentially exacerbate sinus bradycardia and atrioventricular (AV) block by inhibiting sodium and calcium channels.[25]

Serotonin syndrome, a potentially life-threatening adverse effect, results from excess serotonin in both peripheral and central nervous systems. This medical condition can lead to symptoms of neuromuscular excitation and autonomic stimulation. Serotonin syndrome is more likely to happen in patients who take a high dose of SSRIs or have overdosed. This syndrome can also occur in individuals who take multiple serotonergic drugs, especially if they operate through different mechanisms, for instance, combining an SSRI with a monoamine oxidase inhibitor (MAOI).[26]

Symptoms of serotonin syndrome may include autonomic instability, presenting as tachycardia, hypertension, dizziness, diaphoresis, flushing, mydriasis, and an elevated temperature of above 38 °C. Clinical manifestations include nausea, vomiting, diarrhea, and mental status changes, such as agitation, delirium, hallucinations, somnolence, and even coma. Neuromuscular signs such as incoordination, rigidity, clonus, hyperreflexia, tremors, and hypertonicity can also be evident.[26] Severe cases have been reported with ECG changes and seizures.[27][26] Before attempting another antidepressant therapy, a 4-week weaning-off period is recommended to prevent the risk of serotonin syndrome.[28] In rare instances, rhabdomyolysis has been reported.[29]

Drug Withdrawal

Escitalopram can induce withdrawal symptoms, including dizziness, nausea, and lethargy, if discontinued abruptly.[11]

Drug-Drug Interactions

Understanding potential interactions between medications is vital for safe and effective treatment. Various drug combinations involving escitalopram can lead to adverse effects, ranging from serotonin syndrome and bleeding tendencies to increased risk of QT prolongation. Awareness of these interactions is crucial for informed medical decision-making.

  • The concurrent use of escitalopram and rasagiline should be avoided to mitigate the risk of serotonin syndrome.[30]
  • SSRIs, including escitalopram, inhibit platelet function, thereby elevating the risk of bleeding when combined with antiplatelet agents.[31] This propensity for bleeding further intensifies when SSRIs are used in conjunction with low-molecular-weight heparin.[31][32]
  • The risk of bleeding also increases when escitalopram is concomitantly administered with NSAIDs.[33] Furthermore, SSRIs may increase the risk of upper gastrointestinal bleeding when administered with NSAIDs.[34]
  • A study revealed that patients who were given an SSRI in conjunction with aspirin or dual antiplatelet therapy after an acute myocardial infarction experienced an elevated risk of bleeding.[35]
  • Increased risk of QT prolongation exists when escitalopram is administered concurrently with other agents known to prolong QTc intervals, including amiodarone, particularly in patients with chronic kidney disease.[36]


Before prescribing escitalopram, it is essential to conduct a thorough risk assessment, considering hypersensitivity reactions to other medications, especially antidepressants and SSRIs, possible QT prolongation, and the risk of serotonin syndrome in all patients. Notably, this medication is contraindicated for patients with a history of hypersensitivity reactions to escitalopram or citalopram.[18] Furthermore, coadministration of escitalopram with an MAOI is strictly contraindicated due to the risk of causing serotonin syndrome. MAOIs include medications such as phenelzine, selegiline, isocarboxazid, and selegiline.[37]

When starting escitalopram, it is essential to consider the risk of QT prolongation, although it is a relative contraindication. Patients with a family history of long QT syndrome or cases of sudden, premature cardiac death should undergo a thorough assessment. The concurrent use of other medications known to induce prolonged QT syndrome, including antipsychotics (especially older typical antipsychotics), should also be carefully assessed.[23] The combination of escitalopram and pimozide is contraindicated.

Box Warning

Patients taking escitalopram should undergo regular monitoring for mood or behavioral changes, including signs of suicidality. Studies have documented an elevated risk of increased suicidal thoughts and self-destructive behavior in pediatric and adolescent patients taking SSRIs.[1]


Other medications that should be avoided due to the potential risk of inducing serotonin syndrome encompass a range of antidepressants, triptans, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St John's wort. In addition, drugs that impair serotonin metabolism, such as intravenous methylene blue, linezolid, MAOIs, and other psychiatric medications, are also contraindicated.[26][38]

In recent years, pharmacogenetics has played a significant role in assessing the activity of the liver enzyme CYP2C19 as a determinant for contraindicating escitalopram use. CYP2C19 metabolizes escitalopram, and genetic testing can now assess an individual's enzyme activity. Individuals classified as poor metabolizers, or those with reduced activity of this enzyme, tend to exhibit higher concentrations of escitalopram in their bloodstream, consequently increasing the risk of adverse drug reactions.[24] When the status of the CYP2C19 enzyme is known to be weak, it is advisable to assess the necessity of escitalopram use or consider dosage adjustments to prevent severe adverse drug reactions.[39]


Monitoring the effect of pharmacotherapy over time should be done using GAD-7 and the Hamilton Anxiety Scale (HAM-A) for anxiety disorders.[40] In addition, monitoring and quantifying depression severity should be done using the Patient Health Questionnaire-9 (PHQ-9).[41]

Electrolyte disturbances (SSRI-induced SIADH) and ECG changes (QT prolongation) should be evaluated during follow-up visits with a basic metabolic panel and ECG. This is particularly crucial for patients aged 65 or older or those with a family history of arrhythmias.[18] For patients with a history of arrhythmias, it is advisable to conduct follow-up ECGs once escitalopram has reached therapeutic levels. These ECGs are necessary to assess the prolongation of the QT interval. If the QT interval exceeds 500 ms or exhibits a change of more than 60 ms from the baseline, switching to an alternative antidepressant should be considered.[42] RISQ-PATH score can be used to monitor patients with a low risk of QT prolongation with a negative predictive value of 98.0%.[43]


The current maximum recommended dose of escitalopram is 20 mg PO daily. For out-of-hospital isolated SSRI overdoses in patients with minor symptoms (typically less than 5 times their treatment dosage), management should involve at-home observation and close coordination with a local poison control center.[27]

In cases of escitalopram overdose, the most critical clinical concern is the potential for QT prolongation and subsequent TdP arrhythmia, which could be fatal. In cases of reported ingestion of 300 mg or more of escitalopram, administering a single dose of activated charcoal significantly reduced the absorption fraction by 31% and decreased the risk of abnormal QT interval by 35%. Therefore, it is recommended to administer a single dose of activated charcoal to patients who have ingested at least 300 mg of escitalopram in an attempted overdose. Cardiac monitoring for 12 hours is recommended for patients who ingest 300 mg or more of escitalopram and receive activated charcoal.[44] In the event of TdP development, it is recommended to administer magnesium sulfate to patients.[45] Patients with hemodynamically unstable TdP should undergo defibrillation.[25]

The primary approach for patients exhibiting more severe hyperexcitability symptoms is supportive treatment. Besides discontinuing medications, it is essential to implement measures for maintaining appropriate temperature and blood pressure control. Furthermore, agitation can be managed with the use of benzodiazepines. In severe cases of serotonin toxicity, patients may require endotracheal intubation and ventilatory support.[27] For refractory cases to supportive care, medications with known anti-serotonergic properties, such as cyproheptadine, a histamine-1 receptor antagonist, and nonspecific 5-HT1A and 5-HT2A antagonists, may be considered. However, the impact of this antagonistic effect on patient clinical outcomes remains uncertain.[46] Hemodialysis is likely ineffective due to the large volume of distribution of escitalopram.[10][47] A case report has documented an instance of new-onset nocturia associated with the use of expired escitalopram, with no such complaint reported upon transitioning to non-expired medication. This underscores the potential for undesired adverse effects resulting from the use of expired drugs.[48]

Enhancing Healthcare Team Outcomes

The management of depression and anxiety necessitates an interprofessional healthcare team comprising clinicians (MD, DO, NP, and PA), psychiatrists, nurses, therapists, and pharmacists. When using escitalopram for the treatment of depression and anxiety, the interprofessional team must maintain effective communication and collaboration to attain the best possible outcome for the patient. This collaborative effort includes a comprehensive review of the patient's medications to prevent drug interactions and mitigate the risk of adverse events. Furthermore, pharmacists are critical in monitoring drug levels in the blood in cases of overdose, while the monitoring of serum electrolyte levels to detect disturbances is imperative. In situations of overdose, it becomes essential to seek consultation from emergency physicians, medical toxicologists, and intensivists. An interprofessional healthcare team member who identifies issues or has concerns regarding the treatment should promptly engage with other team members to facilitate potential corrective actions. In cases of escitalopram overdose, these coordinated activities and open communication strategies will result in more effective therapeutic outcomes when using escitalopram while minimizing adverse effects.

A retrospective observational study conducted from 2012 to 2014 evaluated the influence of clinical pharmacist (CP) medication review services on patients aged 65 and older who were dealing with polypharmacy. The CP interventions, with a 48.6% acceptance rate among general practitioners, resulted in an 11.2% reduction in the total number of medications and a remarkable 42% decrease in potential X-type drug-drug interactions (pXDDIs). The study also observed a significant 20% reduction in potentially inappropriate medications for older patients. These results underscore the value of implementing CP-led medication review services to improve pharmacotherapy quality and address polypharmacy's challenges, including drugs such as escitalopram.[49] 

A randomized controlled trial (RCT) was conducted, with clinical care being provided by an interprofessional team. This team included registered nurses, personal support workers, home care case managers, the client's primary care providers, psychiatrists, occupational therapists, physical therapists, and social workers. The trial demonstrated that an interprofessional nurse-led mental health intervention effectively reduced healthcare utilization and improved patient outcomes in real-world settings. This positive impact was particularly evident in the context of antidepressant therapy.[50] In a recent RCT, mindfulness-based stress reduction (MBSR) and escitalopram were compared in the treatment of anxiety disorders in 276 adults. Both interventions proved effective over 8 weeks. MBSR demonstrated noninferiority to escitalopram in reducing anxiety levels, affirming its potential as an alternative or complementary approach to pharmacotherapy. Educating patients to make informed treatment decisions is crucial. This comprehensive education empowers patients to engage in their care and optimize their healthcare.[51]



Sanchez C, Reines EH, Montgomery SA. A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike? International clinical psychopharmacology. 2014 Jul:29(4):185-96. doi: 10.1097/YIC.0000000000000023. Epub     [PubMed PMID: 24424469]

Level 3 (low-level) evidence


Strawn JR, Moldauer L, Hahn RD, Wise A, Bertzos K, Eisenberg B, Greenberg E, Liu C, Gopalkrishnan M, McVoy M, Knutson JA. A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder. Journal of child and adolescent psychopharmacology. 2023 Apr:33(3):91-100. doi: 10.1089/cap.2023.0004. Epub     [PubMed PMID: 37074330]

Level 1 (high-level) evidence


Baldwin DS, Asakura S, Koyama T, Hayano T, Hagino A, Reines E, Larsen K. Efficacy of escitalopram in the treatment of social anxiety disorder: A meta-analysis versus placebo. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2016 Jun:26(6):1062-9. doi: 10.1016/j.euroneuro.2016.02.013. Epub 2016 Feb 27     [PubMed PMID: 26971233]

Level 1 (high-level) evidence


Bandelow B, Reitt M, Röver C, Michaelis S, Görlich Y, Wedekind D. Efficacy of treatments for anxiety disorders: a meta-analysis. International clinical psychopharmacology. 2015 Jul:30(4):183-92. doi: 10.1097/YIC.0000000000000078. Epub     [PubMed PMID: 25932596]

Level 1 (high-level) evidence


Stubbs C, Mattingly L, Crawford SA, Wickersham EA, Brockhaus JL, McCarthy LH. Do SSRIs and SNRIs reduce the frequency and/or severity of hot flashes in menopausal women. The Journal of the Oklahoma State Medical Association. 2017 May:110(5):272-274     [PubMed PMID: 28649145]


Marjoribanks J, Brown J, O'Brien PM, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. The Cochrane database of systematic reviews. 2013 Jun 7:2013(6):CD001396. doi: 10.1002/14651858.CD001396.pub3. Epub 2013 Jun 7     [PubMed PMID: 23744611]

Level 1 (high-level) evidence


Kasper S, Sacher J, Klein N, Mossaheb N, Attarbaschi-Steiner T, Lanzenberger R, Spindelegger C, Asenbaum S, Holik A, Dudczak R. Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram. International clinical psychopharmacology. 2009 May:24(3):119-25. doi: 10.1097/YIC.0b013e32832a8ec8. Epub     [PubMed PMID: 19367152]


Berger M, Gray JA, Roth BL. The expanded biology of serotonin. Annual review of medicine. 2009:60():355-66. doi: 10.1146/ Epub     [PubMed PMID: 19630576]

Level 3 (low-level) evidence


Yohn CN, Gergues MM, Samuels BA. The role of 5-HT receptors in depression. Molecular brain. 2017 Jun 24:10(1):28. doi: 10.1186/s13041-017-0306-y. Epub 2017 Jun 24     [PubMed PMID: 28646910]


Rao N. The clinical pharmacokinetics of escitalopram. Clinical pharmacokinetics. 2007:46(4):281-90     [PubMed PMID: 17375980]


Keks N, Hope J, Keogh S. Switching and stopping antidepressants. Australian prescriber. 2016 Jun:39(3):76-83. doi: 10.18773/austprescr.2016.039. Epub 2016 Jun 1     [PubMed PMID: 27346915]


Liu X, Ju G, Yang W, Chen L, Xu N, He Q, Zhu X, Ouyang D. Escitalopram Personalized Dosing: A Population Pharmacokinetics Repository Method. Drug design, development and therapy. 2023:17():2955-2967. doi: 10.2147/DDDT.S425654. Epub 2023 Sep 27     [PubMed PMID: 37789969]


Schoretsanitis G, Spigset O, Stingl JC, Deligiannidis KM, Paulzen M, Westin AA. The impact of pregnancy on the pharmacokinetics of antidepressants: a systematic critical review and meta-analysis. Expert opinion on drug metabolism & toxicology. 2020 May:16(5):431-440. doi: 10.1080/17425255.2020.1750598. Epub 2020 Apr 10     [PubMed PMID: 32238008]

Level 3 (low-level) evidence


Anderson PO, Sauberan JB. Modeling drug passage into human milk. Clinical pharmacology and therapeutics. 2016 Jul:100(1):42-52. doi: 10.1002/cpt.377. Epub 2016 May 13     [PubMed PMID: 27060684]


Uguz F. A New Safety Scoring System for the Use of Psychotropic Drugs During Lactation. American journal of therapeutics. 2021 Jan-Feb 01:28(1):e118-e126. doi: 10.1097/MJT.0000000000000909. Epub     [PubMed PMID: 30601177]


. Escitalopram. Drugs and Lactation Database (LactMed®). 2006:():     [PubMed PMID: 30000334]


By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2023 Jul:71(7):2052-2081. doi: 10.1111/jgs.18372. Epub 2023 May 4     [PubMed PMID: 37139824]


Dodd S, Malhi GS, Tiller J, Schweitzer I, Hickie I, Khoo JP, Bassett DL, Lyndon B, Mitchell PB, Parker G, Fitzgerald PB, Udina M, Singh A, Moylan S, Giorlando F, Doughty C, Davey CG, Theodoros M, Berk M. A consensus statement for safety monitoring guidelines of treatments for major depressive disorder. The Australian and New Zealand journal of psychiatry. 2011 Sep:45(9):712-25. doi: 10.3109/00048674.2011.595686. Epub     [PubMed PMID: 21888608]

Level 3 (low-level) evidence


Cipriani A, Santilli C, Furukawa TA, Signoretti A, Nakagawa A, McGuire H, Churchill R, Barbui C. Escitalopram versus other antidepressive agents for depression. The Cochrane database of systematic reviews. 2009 Apr 15:(2):CD006532. doi: 10.1002/14651858.CD006532.pub2. Epub 2009 Apr 15     [PubMed PMID: 19370639]

Level 1 (high-level) evidence


Kirpekar VC, Joshi PP. Syndrome of inappropriate ADH secretion (SIADH) associated with citalopram use. Indian journal of psychiatry. 2005 Apr:47(2):119-20. doi: 10.4103/0019-5545.55960. Epub     [PubMed PMID: 20711296]


Rondon H, Badireddy M. Hyponatremia. StatPearls. 2023 Jan:():     [PubMed PMID: 29262111]


Hasnain M, Howland RH, Vieweg WV. Escitalopram and QTc prolongation. Journal of psychiatry & neuroscience : JPN. 2013 Jul:38(4):E11. doi: 10.1503/jpn.130055. Epub     [PubMed PMID: 23791140]

Level 3 (low-level) evidence


Beach SR, Celano CM, Sugrue AM, Adams C, Ackerman MJ, Noseworthy PA, Huffman JC. QT Prolongation, Torsades de Pointes, and Psychotropic Medications: A 5-Year Update. Psychosomatics. 2018 Mar-Apr:59(2):105-122. doi: 10.1016/j.psym.2017.10.009. Epub 2017 Nov 3     [PubMed PMID: 29275963]


Cooke MJ, Waring WS. Citalopram and cardiac toxicity. European journal of clinical pharmacology. 2013 Apr:69(4):755-60. doi: 10.1007/s00228-012-1408-1. Epub 2012 Sep 21     [PubMed PMID: 22996077]

Level 3 (low-level) evidence


Tisdale JE, Chung MK, Campbell KB, Hammadah M, Joglar JA, Leclerc J, Rajagopalan B, American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association. Circulation. 2020 Oct 13:142(15):e214-e233. doi: 10.1161/CIR.0000000000000905. Epub 2020 Sep 15     [PubMed PMID: 32929996]


Scotton WJ, Hill LJ, Williams AC, Barnes NM. Serotonin Syndrome: Pathophysiology, Clinical Features, Management, and Potential Future Directions. International journal of tryptophan research : IJTR. 2019:12():1178646919873925. doi: 10.1177/1178646919873925. Epub 2019 Sep 9     [PubMed PMID: 31523132]

Level 3 (low-level) evidence


Bruggeman C, O'Day CS. Selective Serotonin Reuptake Inhibitor Toxicity. StatPearls. 2023 Jan:():     [PubMed PMID: 30521236]


Haddad P. The SSRI discontinuation syndrome. Journal of psychopharmacology (Oxford, England). 1998:12(3):305-13     [PubMed PMID: 10958258]


Mathisen KK, Hardersen R. Escitalopram-associated rhabdomyolysis. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke. 2023 Sep 5:143(12):. doi: 10.4045/tidsskr.23.0093. Epub 2023 Aug 24     [PubMed PMID: 37668131]


Suphanklang J, Santimaleeworagun W, Supasyndh O. Combination of Escitalopram and Rasagiline Induced Serotonin Syndrome: A Case Report and Review Literature. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. 2015 Dec:98(12):1254-7     [PubMed PMID: 27004312]

Level 3 (low-level) evidence


Roweth HG, Yan R, Bedwani NH, Chauhan A, Fowler N, Watson AH, Malcor JD, Sage SO, Jarvis GE. Citalopram inhibits platelet function independently of SERT-mediated 5-HT transport. Scientific reports. 2018 Feb 22:8(1):3494. doi: 10.1038/s41598-018-21348-3. Epub 2018 Feb 22     [PubMed PMID: 29472624]


Samuel NG, Seifert CF. Risk of Bleeding in Patients on Full-Dose Enoxaparin With Venous Thromboembolism and Selective Serotonin Reuptake Inhibitors. The Annals of pharmacotherapy. 2017 Mar:51(3):226-231. doi: 10.1177/1060028016677309. Epub 2016 Nov 13     [PubMed PMID: 27834194]


Bixby AL, VandenBerg A, Bostwick JR. Clinical Management of Bleeding Risk With Antidepressants. The Annals of pharmacotherapy. 2019 Feb:53(2):186-194. doi: 10.1177/1060028018794005. Epub 2018 Aug 6     [PubMed PMID: 30081645]


Anglin R, Yuan Y, Moayyedi P, Tse F, Armstrong D, Leontiadis GI. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. The American journal of gastroenterology. 2014 Jun:109(6):811-9. doi: 10.1038/ajg.2014.82. Epub 2014 Apr 29     [PubMed PMID: 24777151]

Level 1 (high-level) evidence


Labos C, Dasgupta K, Nedjar H, Turecki G, Rahme E. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2011 Nov 8:183(16):1835-43. doi: 10.1503/cmaj.100912. Epub 2011 Sep 26     [PubMed PMID: 21948719]

Level 2 (mid-level) evidence


Snitker S, Doerfler RM, Soliman EZ, Deo R, St Peter WL, Kramlik S, Fischer MJ, Navaneethan S, Delafontaine P, Jaar BG, Ojo A, Makos GK, Slaven A, Weir MR, Zhan M, Fink JC, for CRIC Study Investigators. Association of QT-Prolonging Medication Use in CKD with Electrocardiographic Manifestations. Clinical journal of the American Society of Nephrology : CJASN. 2017 Sep 7:12(9):1409-1417. doi: 10.2215/CJN.12991216. Epub 2017 Aug 9     [PubMed PMID: 28793999]


Sabri MA, Saber-Ayad MM. MAO Inhibitors. StatPearls. 2023 Jan:():     [PubMed PMID: 32491327]


Gatti M, Raschi E, De Ponti F. Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic/pharmacodynamic analysis. European journal of clinical pharmacology. 2021 Feb:77(2):233-239. doi: 10.1007/s00228-020-02990-1. Epub 2020 Sep 8     [PubMed PMID: 32901348]


Petry N, Lupu R, Gohar A, Larson EA, Peterson C, Williams V, Zhao J, Wilke RA, Hines LJ. CYP2C19 genotype, physician prescribing pattern, and risk for long QT on serotonin selective reuptake inhibitors. Pharmacogenomics. 2019 Apr:20(5):343-351. doi: 10.2217/pgs-2018-0156. Epub 2019 Apr 15     [PubMed PMID: 30983508]


Ruiz MA, Zamorano E, García-Campayo J, Pardo A, Freire O, Rejas J. Validity of the GAD-7 scale as an outcome measure of disability in patients with generalized anxiety disorders in primary care. Journal of affective disorders. 2011 Feb:128(3):277-86. doi: 10.1016/j.jad.2010.07.010. Epub 2010 Aug 9     [PubMed PMID: 20692043]


Beard C, Hsu KJ, Rifkin LS, Busch AB, Björgvinsson T. Validation of the PHQ-9 in a psychiatric sample. Journal of affective disorders. 2016 Mar 15:193():267-73. doi: 10.1016/j.jad.2015.12.075. Epub 2015 Dec 31     [PubMed PMID: 26774513]

Level 1 (high-level) evidence


Sheeler RD, Ackerman MJ, Richelson E, Nelson TK, Staab JP, Tangalos EG, Dieser LM, Cunningham JL. Considerations on safety concerns about citalopram prescribing. Mayo Clinic proceedings. 2012 Nov:87(11):1042-5. doi: 10.1016/j.mayocp.2012.07.009. Epub 2012 Sep 24     [PubMed PMID: 23018033]


Vandael E, Vandenberk B, Vandenberghe J, Spriet I, Willems R, Foulon V. Development of a risk score for QTc-prolongation: the RISQ-PATH study. International journal of clinical pharmacy. 2017 Apr:39(2):424-432. doi: 10.1007/s11096-017-0446-2. Epub 2017 Mar 9     [PubMed PMID: 28281228]


van Gorp F, Duffull S, Hackett LP, Isbister GK. Population pharmacokinetics and pharmacodynamics of escitalopram in overdose and the effect of activated charcoal. British journal of clinical pharmacology. 2012 Mar:73(3):402-10. doi: 10.1111/j.1365-2125.2011.04091.x. Epub     [PubMed PMID: 21883384]


Thomas SH, Behr ER. Pharmacological treatment of acquired QT prolongation and torsades de pointes. British journal of clinical pharmacology. 2016 Mar:81(3):420-7. doi: 10.1111/bcp.12726. Epub 2015 Oct 26     [PubMed PMID: 26183037]


Graudins A, Stearman A, Chan B. Treatment of the serotonin syndrome with cyproheptadine. The Journal of emergency medicine. 1998 Jul-Aug:16(4):615-9     [PubMed PMID: 9696181]

Level 3 (low-level) evidence


Nelson LS, Erdman AR, Booze LL, Cobaugh DJ, Chyka PA, Woolf AD, Scharman EJ, Wax PM, Manoguerra AS, Christianson G, Caravati EM, Troutman WG. Selective serotonin reuptake inhibitor poisoning: An evidence-based consensus guideline for out-of-hospital management. Clinical toxicology (Philadelphia, Pa.). 2007 May:45(4):315-32     [PubMed PMID: 17486478]

Level 1 (high-level) evidence


Md Fİ. Nocturia Caused by Expired Escitalopram. The primary care companion for CNS disorders. 2023 Jul 18:25(4):. pii: 22cr03440. doi: 10.4088/PCC.22cr03440. Epub 2023 Jul 18     [PubMed PMID: 37471478]


Stuhec M, Gorenc K, Zelko E. Evaluation of a collaborative care approach between general practitioners and clinical pharmacists in primary care community settings in elderly patients on polypharmacy in Slovenia: a cohort retrospective study reveals positive evidence for implementation. BMC health services research. 2019 Feb 13:19(1):118. doi: 10.1186/s12913-019-3942-3. Epub 2019 Feb 13     [PubMed PMID: 30760276]

Level 2 (mid-level) evidence


Markle-Reid M, McAiney C, Forbes D, Thabane L, Gibson M, Browne G, Hoch JS, Peirce T, Busing B. An interprofessional nurse-led mental health promotion intervention for older home care clients with depressive symptoms. BMC geriatrics. 2014 May 10:14():62. doi: 10.1186/1471-2318-14-62. Epub 2014 May 10     [PubMed PMID: 24886344]

Level 1 (high-level) evidence


Hoge EA, Bui E, Mete M, Dutton MA, Baker AW, Simon NM. Mindfulness-Based Stress Reduction vs Escitalopram for the Treatment of Adults With Anxiety Disorders: A Randomized Clinical Trial. JAMA psychiatry. 2023 Jan 1:80(1):13-21. doi: 10.1001/jamapsychiatry.2022.3679. Epub     [PubMed PMID: 36350591]

Level 1 (high-level) evidence